Definitive Contract HHSN261201300048C
Award Date
9/13/13
Potential Completion Date
9/12/16
Potential Value
$1M
Federal Agency
National Cancer Institute
Awardee
Lectenz Bio, Inc.
Ultimate Awardee
Not listed
NAICS Category
541711 - Research and Development in Biotechnology
Federal Contract Vehicle
Set-Aside Type
No Set-Aside Used
Extent Competed
Full and Open Competition
Major Defense Program
Not listed
Pricing Type
Cost Plus Fixed Fee
Place of Performance
Athens, GA 30602, USA
Solicitation Procedures
Negotiated Proposal / Quote
Number Of Offers Received
5
Legislative Mandate
Not listed
National Interest Action
Not listed
Research Type
Not listed
Primary Consortia Member
Not listed
Similar Awards
This is a Small Business Innovation Research (SBIR) contract awarded by the National Institutes of Health's (NIH) National Cancer Institute (NCI) to Glycoscientific, L.L.C., a small business research company. The contract is for the development of glycosylation-specific research reagents, including antibodies and aptamers, under SBIR Topic 294 Phase I. The contract has a ceiling value of $149,951 and was awarded on a firm fixed-price basis. This contract was set aside for total small business...
This contract was awarded by the Department of Health and Human Services' National Institutes of Health (NIH) National Institute of Allergy and Infectious Diseases (NIAID) to Glycoscientific, L.L.C., a small business, to provide reagents for immunologic analysis of non-mammalian and underrepresented mammalian models. The contract has a potential value of $600,000.00 and is a definitive, firm-fixed-price contract with a completion date of August 31, 2025. This contract was set aside for total...
<p>This is a $999,898 Firm Fixed Price contract awarded by the National Cancer Institute (NCI), a civilian federal agency, to Glycobia Inc., a small business, under the SBIR Phase II program. The contract is for the development of chemically defined glycan libraries for use as reference standards and in glycomics research, under a joint NCI-NIGMS program. The contract has a small business set aside designation and runs through September 2018.</p>
<p>This is a Small Business Innovation Research (SBIR) Phase II contract awarded by the National Cancer Institute (NCI), a civilian agency, to Omicron Biochemicals, Inc. The $999,991.00 fixed-price contract is for the "Synthesis of High-Mannose N-Glycans" and was awarded on September 18, 2015, with a completion date of September 17, 2017. The contract is a definitive contract, indicating it is a stand-alone award rather than under a larger contract vehicle.</p>
<p>This is a Small Business Innovation Research (SBIR) Phase I contract awarded by the National Cancer Institute (NCI), a civilian agency, to Biotex, Inc. The contract is for the development of glycosylation-specific research, with a ceiling value of $149,919.00 and a completion date of October 14, 2012. The contract is a definitive contract with a firm fixed-price pricing type. This SBIR Phase I action is a set-aside for small businesses.</p>
This federal contract award, valued at $299,450.00, was issued by the National Cancer Institute, a civilian agency, to Glycobia, Inc., a for-profit limited liability company and manufacturer of goods. The contract is for a Small Business Innovation Research (SBIR) Program Phase I project titled "BOTTOM-UP GLYCOENGINEERING LIBRARY OF N-GLYCANS". The contract has a firm fixed price pricing type and was awarded on September 12, 2013 with a completion date of June 30, 2014. Glycobia,...
This is a Phase II Small Business Innovation Research (SBIR) contract awarded by the National Cancer Institute (NCI), a civilian federal agency, to Siamab Therapeutics, Inc. The purpose of the contract is to develop technologies to characterize glycan moieties of glycoproteins in order to enhance the diagnostic capability of protein-based biomarkers. The specific goals include expanding the number of features for an existing sialic acid glycan array, optimizing the serum assay protocol,...
This is a $1,646,541.00 Cost Plus Fixed Fee contract awarded by the National Cancer Institute (NCI), a component of the National Institutes of Health (NIH) within the U.S. Department of Health and Human Services (HHS), to Glycan Therapeutics Corporation, a small disadvantaged business. The contract is for the chemoenzymatic synthesis of heparin sulfate under the Small Business Innovation Research (SBIR) Phase II program. The work is focused on developing synthetic heparan sulfate...
The National Institute of Allergy and Infectious Diseases (NIAID), a civilian agency within the Department of Health and Human Services, awarded a $224,751 firm-fixed-price contract to Glucosentient Inc., a small business, for the development of a "TELE-MONITORING FOR INFECTIOUS DISEASES: A REMOTE SYSTEM FOR ASSESSING PATIENT PARAMETERS AND SPECIMEN ANALYSIS." The contract, which has an ultimate completion date of August 29, 2017, was set aside for small businesses. Glucosentient, a...
This is a firm-fixed-price SBIR Phase I contract awarded by the National Cancer Institute (NCI), a civilian agency, to Chemily LLC, a small business. The contract is for the "CHEMO-ENZYMATIC SYNTHESIS OF STRUCTURALLY DEFINED HYBRID AND COMPLEX-TYPE N-GLYCAN LIBRARIES" and has a ceiling value of $299,544.00. The contract was awarded on September 12, 2013, with an ultimate completion date of October 30, 2014. As an SBIR Phase I contract, this award supports early-stage research and...